RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - PRODUZIONE E CATABOLISMO DELLA BETA-AMILOIDE IN PAZIENTI CON MALATTIA DI ALZHEIMER E MILD COGNITIVE IMPAIRMENT: STUDI IN VITRO E MARKERS EX VIVO
• 2 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 3 - RUOLO DELLE CELLULE DENDRITICHE, DELLE CITOCHINE E DEGLI ORMONI STEROIDEI SESSUALI NELLA STORIA NATURALE DELLE MALATTIE EPATICHE CRONICHE
• 4 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 5 - Ruolo patogenetico del Brain-derived neurotrophic factor (BDNF) nell'eziologia delle patologie neurodegenerative: dai modelli animali allo studio nell'uomo.
• 6 - Effetti clinici e molecolari dell'eccesso di glucocorticoidi
• 7 - PEROSSIDAZIONE LIPIDICA, ATTIVAZIONE PIASTRINICA ED INFIAMMAZIONE ASSOCIATI A RIDOTTI LIVELLI DI LIPOPROTEINE AD ALTA DENSITA' (HDL)
• 8 - Interruttori molecolari che controllano l'omeostasi dei sistemi metabolici e vascolari: dai modulatori del RNA a quelli della trasmissione del segnale
• 9 - PATOGENESI DELLA STEATOSI NELLA STEATOEPATITE NON ALCOLICA (NAFLD) E NELLA EPATITE CRONICA HCV CORRELATA.
• 10 - Nefrolitiasi calcica e ostepatie associate: studio delle interazioni tra cause genetiche e nutrizionali e dei meccanismi patogenetici.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • MEDICINA INTERNA
  • GASTROENTEROLOGIA
  • ENDOCRINOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1) Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
2) Falck-Ytter Y, Younossi ZM, Marchesini G, McCulluogh AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis 2001; 21: 17-26.
3) Matteoni C, Younossi Z, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
4) Cortez-Pinto H, Camilo M, Baptista A, DeOliveira A, DeMoura M. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353-358
5) Lonardo A, Loria P., Carulli N. Insulin resistance in non-alcoholic fatty liver disease. In: Steatohepatitis (NASH and ASH).Leuschner U, James O, Dancygier H Eds. Kluwer
6) Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulinresistance. Am J Med. 1999;107:450-5.
7) Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-78.
8) Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
9) Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004 Jan;39(1):179-87.
10) Green RM. NASH--hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14-7.
11) Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004, in press
12) Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2699-705
13) Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:185-94.
14) Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-97.
15) Roulot D, Degott C, Chazouilleres O, et al. Vascular involvement of the liver in Turner's syndrome. Hepatology. 2004;39:239-47.
16) Maffei L, Murata Y, Rochira V et al. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab. 2004;89:61-70.
17) Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol. 2003;180:129-34.
18) Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease.Gastroenterology. 2002;122:1649-57.
19) Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-19.
20) Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J.Hepatol. 1997;26 Suppl 1:13
21) Chalasani N, Gorski JC, Asghar MS et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology. 2003;37:544-50.
22) Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
23) Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
24) Haque M, Mirshahi F, Campbell-Sargent C, et al. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondria depletion. Hepatology 36. 20-2-2002.
25) Stewart SF et al. Oxidative stress as a trigger for cellular immune response in patients with alcoholic liver disease. Hepatol. 39,197-203, 2004.
26) Albano E. et al. Oxidative stress is an independent risk factor for the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. Hepatol 38:720, 2003 (Abstract).
27) Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931-9.
28) Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance.
29) Rudich A, Kozlovsky N, Potashnik R, Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol. 1997 May;272(5 Pt 1):E935-40.
30) Day CP, Daly AK. The genetic basis for non-alcoholic and alcoholic steatohepatitis. In: Steatohepatitis (NASH and ASH).Leuschner U, James O, Dancygier H Eds. Kluwer Academic Publishers Dordrecht 2001, pages 104-113.
31) Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J med 1998;338:1042-1050.
32) Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996 Jan;58(1):35-41.
33) Gaull G,Sturman JA, Schaffer F. Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies. J Pedatr. 1974;84:381.390.
34) Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation if the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263-1273. Gastroenterology. 2002 Feb;122(2):274-80.
35) Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004;30:13-9.
36) Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A. 1999;96:2327-32.
37) Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-9.
38) Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates profibrogenic responses and remodeling of extracellular matrix in the rat liver. Gastroenterology 2002;122:1399-410.
39) Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med. 2003;81:218-26.
40) Minn AH, Patterson NB, Pack S, et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun. 2003;310:641-5.
41) 17. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303:1195-8.
42) Wolf G. Adiponectin: a regulator of energy homeostasis. Nutr Rev. 2003;61:290-2.
43) Kamada Y, Tamura S, Kiso S et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796-807.
44) Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112:91-100.
45) Heilbronn LK, Smith SR, Ravussin E. The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des. 2003;9:1411-8.
46) Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-64.

Parole Chiave

STEATOSI; STEATOEPATITE NON ALCOLICA; INSULINORESISTENZA; FATTORI GENETICI; STRESS OSSIDATIVO; MITOCONDRI; EPATITE C; OMOCISTEINA; ADIPOCHINE